Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesWillow Biosciences Inc

Willow Biosciences Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2025-09-25T20:00:14.015103Z
Market Cap
5.15M

Momentum Score

…

Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.03
Low
0.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
6.37M
Revenue Per Share
0.23
Gross Profit TTM
1.31M
Debt / Equity
0.63
ROE
-971.43%
Net Debt
0.38M
ROCE
-3708.27%
Diluted EPS TTM
-0.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.76M -6.14M -33.95M -46.15M -
Net income -14.81M 10.51M -51.16M -44.57M -
Selling general administrative 8.29M 7.79M 6.42M 8.24M -
Selling and marketing expenses 0.81M 0.82M - - -
Gross profit 0.82M 0.13M 0.01M 0.00M -
Reconciled depreciation 2.65M 3.19M 3.18M 2.17M -
Ebit -18.39M -23.33M -23.06M -46.15M -1.64M
Ebitda -15.45M -19.57M -13.51M -10.80M -
Depreciation and amortization 2.94M 3.76M 9.55M 35.35M -
Operating income -18.39M -23.33M -23.06M -46.15M -
Other operating expenses 19.22M 23.31M 16.86M 13.08M -
Interest expense 0.03M 0.03M 0.04M 0.05M 0.00M
Tax provision 0.05M - 0.00M -1.58M -
Interest income 0.30M 0.41M 0.15M 0.06M -
Net interest income 0.27M 0.39M 0.12M 0.06M -
Income tax expense 0.05M -16.65M 17.21M -1.58M -
Total revenue 0.82M 0.13M 0.01M 0.00M -
Total operating expenses 19.22M 23.31M 16.86M 13.08M -
Total other income expense net 3.63M 17.19M -10.88M -33.13M -
Net income from continuing ops -14.81M -6.14M -33.95M -44.57M -
Net income applicable to common shares -14.81M -6.14M -33.95M -44.57M -1.64M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.49M 6.67M 18.15M 35.02M 21.86M
Intangible assets - 0.01M - - 0.00M
Other current assets - 0.62M 0.64M 0.73M 0.56M
Total liab 2.99M 3.24M 1.77M 5.33M 22.42M
Total stockholder equity -0.51M 3.44M 16.37M 29.68M -0.56M
Other current liab - 0.32M 1.09M 0.76M 0.98M
Common stock - 118.18M 118.07M 118.03M 83.17M
Capital stock 120.89M 118.18M 118.07M 118.03M 83.17M
Retained earnings -127.87M -121.69M -108.66M -93.84M -87.70M
Other liab - - 0.02M 3.77M 20.58M
Other assets - - 0.00M 0.10M 0.09M
Cash 0.33M 3.15M 11.01M 30.12M 15.89M
Cash and equivalents - - 11.01M 30.12M 15.89M
Total current liabilities 1.99M 1.81M 1.72M 1.41M 1.56M
Current deferred revenue - 0.13M - 0.01M -
Net debt 0.38M -0.99M -10.34M -29.32M -15.03M
Short term debt - 0.73M 0.63M 0.64M 0.59M
Short long term debt - 0.08M - - -
Short long term debt total - 2.16M 0.66M 0.80M 0.87M
Other stockholder equity - 7.31M 7.32M 5.91M 4.29M
Property plant equipment - - 1.92M 3.60M 4.67M
Total current assets 0.66M 4.17M 16.23M 31.27M 17.03M
Net tangible assets - - - 29.63M -0.62M
Short term investments 0.02M 0.02M 4.02M - 0.00M
Net receivables 0.04M 0.17M 0.28M 0.09M 0.29M
Long term debt 0.71M 0.59M - - -
Inventory 0.06M 0.22M 0.28M 0.38M 0.29M
Accounts payable - 0.64M 1.09M 0.76M 0.98M
Accumulated other comprehensive income - -0.37M -0.36M -0.41M -0.32M
Common stock total equity - - - - 83.17M
Non currrent assets other - 0.06M - 0.10M 0.09M
Non current assets total 1.83M 2.50M 1.92M 3.75M 4.83M
Capital lease obligations 1.26M 1.48M 0.66M 0.80M 0.87M
Long term debt total - - 0.03M 0.16M 0.28M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.55M -1.67M -0.84M -6.83M -
Change to liabilities 0.00M 0.00M 0.00M 0.00M 0.04M
Total cashflows from investing activities -4.55M -1.67M -0.84M -6.83M -0.20M
Net borrowings -0.72M -0.64M -0.65M -0.49M -0.02M
Total cash from financing activities -0.72M 34.13M 9.89M 35.26M 1.32M
Change to operating activities 0.13M -0.32M -0.21M -0.35M -0.04M
Net income -14.81M -6.14M -33.95M -44.57M -1.64M
Change in cash -19.11M 14.22M -3.75M 19.27M -0.22M
Begin period cash flow 30.12M 15.89M 19.64M 0.37M 0.09M
End period cash flow 11.01M 30.12M 15.89M 19.64M 0.37M
Total cash from operating activities -13.86M -18.23M -12.78M -9.16M -1.33M
Issuance of capital stock 0.00M 26.73M 10.52M 27.38M -
Depreciation 2.65M 3.19M 3.18M 2.17M 0.05M
Other cashflows from investing activities -3.87M -0.03M -0.01M -0.18M -0.18M
Change to account receivables - - - - -0.33M
Sale purchase of stock 0.00M 34.77M 10.52M 35.87M -
Other cashflows from financing activities -4.55M 8.03M 0.03M 8.38M -0.01M
Change to netincome -1.82M -14.96M 18.20M 33.59M 0.59M
Capital expenditures 0.68M 1.77M 1.00M 6.71M 0.20M
Change in working capital 0.13M -0.32M -0.21M -0.35M -
Stock based compensation 1.46M 1.70M 0.95M 2.59M -
Other non cash items -3.28M -16.67M 17.24M 32.58M -
Free cash flow -14.54M -19.99M -13.78M -15.87M -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CURA
Curaleaf Holdings Inc.		 -
-%		 14.23 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.24
2.10%		 11.65 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.09
1.89%		 4.85 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.29
7.80%		 4.01 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Willow Biosciences Inc

Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.

202, 1201-5th Street SW, Calgary, AB, Canada, T2R 0Y6

403-910-5140

https://www.willowbio.com

19

Name Title Year Born
Dr. Peter Seufer-Wasserthal Ph.D. Pres, CEO & Chairman 1962
Mr. Travis Doupe Chief Financial Officer 1972
Dr. Chris Savile Chief Operations Officer NA
Mr. Simon Hickling Ph.D. Sr. VP of Bus. Devel. NA
Dr. Trish Choudhary VP of R&D NA
Mr. Troy T. Talkkari VP of Corp. Devel. NA
Mr. Sanjib Singh Gill L.L.B. Corp. Sec. 1976
Mr. Travis Doupe Chief Financial Officer 1971
Dr. Chris Savile President, Director & CEO NA
Mr. Sanjib Singh Gill L.L.B. Corporate Secretary 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…